Suppression of pancreatic cancer proliferation through TXNIP-mediated inhibition of the MAPK signaling pathway: TXNIP inhibits pancreatic cancer via the MAPK pathway

• Published in: Acta biochimica et biophysica Sinica 2024-01, Vol.56 (4), p.513-524
• Main Authors: Fei, Qinglin, Jin, Kaizhou, Shi, Saimeng, Li, Tianjiao, Guo, Duancheng, Lin, Mengxiong, Yu, Xianjun, Wu, Weiding, Ye, Longyun
• Format: Article
• Language: English
• ISSN: 1672-9145; 1745-7270
• DOI: 10.3724/abbs.2023286

Thioredoxin-interacting protein (TXNIP) is a crucial thioredoxin-binding protein that is recognized as a tumor suppressor in diverse malignancies, such as breast cancer, lung cancer, hepatocellular carcinoma, and thyroid cancer. However, the specific role and molecular mechanisms of TXNIP in the pathogenesis and progression of pancreatic cancer cells have not been determined. In this study, we investigate the relationship between TXNIP expression and overall survival prognosis in pancreatic cancer patients. Mechanistic studies are conducted to reveal the role of TXNIP in pancreatic cancer cell proliferation, migration, and regulation during malignancy. Our findings indicate that patients with high TXNIP expression have a more favorable prognosis. In vitro experiments with pancreatic cell lines show that overexpression of TXNIP suppresses the proliferation and migration of pancreatic cancer cells. Furthermore, we find that TXNIP inhibits the activation of the MAPK signaling pathway, thereby decreasing the malignant potential of pancreatic cancer. In conclusion, our study reveals TXNIP as a promising new predictive marker and therapeutic target for pancreatic cancer.